Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
Authors:
- 24 May 2012
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 134 (2) , 875-880
Abstract
Two selective estrogen receptor modulators, tamoxifen and raloxifene, have been shown in randomized clinical trials to reduce the risk of developing primary invasive breast cancer in high-risk women. In 1998, the U.S. Food and Drug Administration (FDA) used these studies as a basis for approving tamoxifen for primary breast chemoprevention in both premenopausal and postmenopausal women at high risk. In 2007, the FDA approved raloxifene for primary breast cancer chemoprevention for postmenopausal women. Data from the year 2010 National Health Interview Survey were analyzed to estimate the prevalence of tamoxifen and raloxifene use for chemoprevention of primary breast cancers among U.S. women. Prevalence of use of chemopreventive agents for primary tumors was 20,598 (95 % CI, 518–114,864) for U.S. women aged 35–79 for tamoxifen. Prevalence was 96,890 (95 % CI, 41,277–192,391) for U.S. women aged 50–79 for raloxifene. Use of tamoxifen and raloxifene for prevention of primary breast cancers continues to be low. In 2010, women reporting medication use for breast cancer chemoprevention were primarily using the more recently FDA approved drug raloxifene. Multiple possible explanations for the low use exist, including lack of awareness and/or concern about side effects among primary care physicians and patients.Keywords
This publication has 38 references indexed in Scilit:
- Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or OlderJournal of Clinical Oncology, 2011
- Risk scores and decision making: the anatomy of a decision to reduce breast cancer riskJournal of Nursing and Healthcare of Chronic Illness, 2010
- Patient Decisions About Breast Cancer Chemoprevention: A Systematic Review and Meta-AnalysisJournal of Clinical Oncology, 2010
- Prevalence of Tamoxifen Use for Breast Cancer Chemoprevention Among U.S. WomenCancer Epidemiology, Biomarkers & Prevention, 2010
- Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aidBreast Cancer Research and Treatment, 2009
- What Is My Cancer Risk? How Internet-Based Cancer Risk Assessment Tools Communicate Individualized Risk Estimates to the Public: Content AnalysisJournal of Medical Internet Research, 2009
- American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk ReductionJournal of Clinical Oncology, 2009
- Explanations for side effect aversion in preventive medical treatment decisions.Health Psychology, 2009
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary PreventionAnnals of Surgical Oncology, 2001